STRATEC Biomedical (SBS) Q2 2026 Earnings Report

The call presented a mixed but constructive picture: significant operational and financial positives (a material Q2 operational recovery, a strong cash-flow turnaround, systems revenue growth and debt reduction) were offset by meaningful short-term headwinds (an H1 revenue decline, an unusually weak consumables/maintenance parts trend, elevated inventories, supply-chain pressures and continued customer order volatility). Management confirmed 2026 guidance and set credible multi-year growth and margin targets, while emphasizing cost discipline and product pipeline execution. Given the sizable cash-flow and margin improvements together with confirmed guidance, but acknowledging persistent near-term demand and supply risks, the tone is cautiously optimistic.

STRATEC confirmed its 2026 guidance, calling for medium‑to‑high single‑digit sales growth on a constant‑currency basis with the year highly back‑end loaded (Q4 historically contributes ~30–33% of annual revenue and management expects Q4 toward the top end of that range, with Q3 roughly in the same ballpark as Q2); adjusted EBIT margin for 2026 is expected to be approximately at last year’s ~10% level, CapEx is guided to a 6.5–8.5%‑of‑sales corridor (management expects to be at the lower edge), and there is a continuing focus on working‑capital efficiency and cash‑flow improvement; medium‑term targets are 2025–2028 revenue CAGR of 6–8% and 2028–2030 CAGR of 10–12%, with adjusted EBIT margin of at least 13% by 2028 and at least 15% by 2030—guidance is underpinned by H1 results (revenue €112.5m, down 5.1% nominal / 3.3% cc; H1 adjusted EBIT €7.7m, 6.9% margin; free cash flow €23.5m) and a net debt position of €96.7m (net debt / LTM EBITDA 2.9x).